27th German Cancer Congress Berlin 2006
German Cancer Society (Frankfurt/M.)
22. - 26.03.2006, Berlin
Lung Cancer
Meeting Abstract
(OP140)
[Full Text]
A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin), in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Reck M, Blumenschein Jr. G, Jotte R, von Pawel J, Miller WH, Khuri F, Rigas JR, Negro-Vilar A, Gatzemeier U[Full Text]
Meeting Abstract
(OP141)
[Full Text]
Long Term Results of Lung Cancer Treatment - Clinical and Population-Based Aspects
Schmidt M, Hölzel D[Full Text]
Meeting Abstract
(OP142)
[Full Text]
Hypofractionated stereotactic radiotherapy (hSRT) of NSCLC Stage I
Zimmermann F, Geinitz H, Schill S, Schratzenstaller U, Nieder C, Molls M[Full Text]
Meeting Abstract
(OP143)
[Full Text]
Identification of patients potentially benefiting from concomitant EGF-R inhibition and chemotherapy: CHALLENGE trial: Erlotinib followed by Gemcitabine/Cisplatin +/- Erlotinib induction in patients with NSCLC IIIA (N2)/IIIB (N3) monitored by microarray analyses
Overbeck TR, Danner B, Dörge H, Wenleder S, Hemmerlein B, Meller J, Baum RP, Wolf J, Schirren J, Müller RP, Wolf M, Griesinger F[Full Text]
Meeting Abstract
(OP144)
[Full Text]
Single-Agent (SA) Therapy of Docetaxel (D) and Gemcitabine (G) for Patients (pts) in Advanced Non-small Cell Lung Cancer (NSCLC): Results of Three Consecutive Randomized Multicentre Trials
Manegold C, Thatcher N, Kortsik C, Koschel G, Mezger J, Schott von Römer K, Pilz LR[Full Text]
Meeting Abstract
(OP145)
[Full Text]
Gefitinib for treatment of non small cell lung cancer (NSCLC): Single center clinical results and mutation analysis of the epidermal growth factor receptor (EGFR) kinase domain
Frickhofen N, Neugebauer B, Hengstler S, Labenz S, Fuhr HG, Schirren J, Fisseler-Eckhoff A, Serve H, Müller-Tidow C[Full Text]
Meeting Abstract
(OP146)
[Full Text]
First- and Secondline chemotherapy with Pemetrexed alone or in combination with Carboplatin in malignant pleural mesothelioma
Storbeck B, Gatzemeier U, Reck M[Full Text]
Meeting Abstract
(PO147)
[Full Text]
Epoetin alfa (EPO) and survival in patients with non-resectable NSCLC – Interim results
Debus J, Hindermann S, Morr H, Mezger J, Sebastian M, Angermund R, Drings P[Full Text]
Meeting Abstract
(PO148)
[Full Text]
Intensity-modulated Radiotherapy (IMRT) of Lung Tumors in 50 Patients: Protection of Lung Tissue and low Toxicity
Huhnt W, Buchali A[Full Text]
Meeting Abstract
(PO149)
[Full Text]
Side effects of hypofractionated extracranial stereotactic radiotherapy (ESRT) of malignant tumours of the lung
Zimmermann F, Geinitz H, Schill S, Schratzenstaller U, Thamm R, Molls M[Full Text]
Meeting Abstract
(PO150)
[Full Text]
Sorafenib (BAY 43-9006) in Patients with Relapsed or Refractory Advanced Non-Small-Cell Lung Carcinoma – a phase II study
Reck M, Blumenschein Jr. G, Bernard I, Scheuring U, Gatzemeier U[Full Text]
Meeting Abstract
(PO151)
[Full Text]
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP)
Gauler TC, Tewes M, Sailer V, Bildat S, Schütt P, Korfee S, Stattaus J, Toetsch M, Seeber S, Eberhardt W[Full Text]
Meeting Abstract
(PO152)
[Full Text]
First experiences with oral tyrosine kinase inhibitor Erlotinib in patients with advanced Non small cell lung cancer within an Expanded Access Program (EAP Germany)
Schneider CP[Full Text]
Meeting Abstract
(PO153)
[Full Text]
Correlation of PTTG-1 expression with survival in small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC)
Geddert H, Rehfeld N, Atamna A, Rohrbeck A, Gabbert HE, Kronenwett R, Haas R, Rohr UP[Full Text]
Meeting Abstract
(PO154)
[Full Text]
Genetic-based classification of lung cancer: correlation between nuclear DNA content, chromosomal alterations and morphology
Amin Kotb WFM, Petersen I[Full Text]
Meeting Abstract
(PO155)
[Full Text]
Single-agent chemotherapy with Mitomycin for advanced non-small cell lung cancer patients with reduced Performance Status
Guschall WR, Dittrich I[Full Text]
Meeting Abstract
(PO156)
[Full Text]
Tumor specific MUC1 glycosylation correlates with improved post-surgical survival of non-small cell lung cancer patients with lymphatic or distant metastasis
Wiewrodt R, Kuemmel A, Single K, Bittinger F, Faldum A, Sebastian M, Taube C, Goletz S, Buhl R[Full Text]
Meeting Abstract
(PO157)
[Full Text]
Retrospective analysis of second-line chemotherapy in relapsed NSCLC patients who had received first-line paclitaxel/carboplatin chemotherapy in a randomized phase III trial
Nagel S, Raziq H, Blankenburg T, Schaedlich S, Schuette W[Full Text]
Meeting Abstract
(PO158)
[Full Text]
Predictive factors for patients with small cell lung carcinoma (SCLC) undergoing first-line ACE chemotherapy – results after long term follow-up of median 7.5 years
Brueckl WM, Herbst L, Lechler A, Zirlik S, Fuchs F, Brunner T, Klein P, Papadopoulos T, Hohenberger W, Hahn EG, Wiest GH[Full Text]
Meeting Abstract
(PO160)
[Full Text]
Successful in-patient rehabilitation of lung cancer patients - predictors and outcome
Riesenberg H, Lübbe AS[Full Text]
Meeting Abstract
(PO161)
[Full Text]
Fast response of chemotherapy-refractory bronchiolo-alveolar carcinoma to erlotinib
Gütz S, Schwartz EK, Gutjahr K, Gillissen A[Full Text]
Meeting Abstract
(PO162)
[Full Text]
Pulmonary mucinous cystadenocarcinoma – a rare disease successfully treated by thoracoscopic approach?
Möbius C, Ott R, Winkler J, Tannapfel A, Hauss J, Eichfeld U[Full Text]
Meeting Abstract
(PO163)
[Full Text]
Präoperatives Staging des nicht-kleinzelligen Bronchialkarzinoms mit PET/CT
Buck AK, Blumstein NM, Blümel C, Glatting G, Pauls S, Mottaghy FM, Halter G, Sunder-Plassmann L, Reske SR[Full Text]
Meeting Abstract
(PO164)
[Full Text]
Tumorgrading: An important prognostic factor in diagnostic of non-smal-cell-lung-cancer, stadium pT1
Neugebauer B, Schirren J, Beqiri S, Fisseler-Eckhoff A[Full Text]